ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

ABSTRACT:

SUBMITTER: Strati P 

PROVIDER: S-EPMC6355491 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature